Ernexa Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ERNA Nasdaq 2836 www.ernexatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ernexa Therapeutics Inc.

Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic - Oct 1st, 2026 7:20 am
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND - Sep 30th, 2026 6:32 am
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy - Sep 29th, 2026 7:15 am
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors - Sep 17th, 2026 6:42 am
Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing - Sep 15th, 2026 6:42 am
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Sep 14th, 2026 7:05 am
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference - Aug 27th, 2026 7:01 am
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies - Jul 24th, 2026 7:20 am
Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA) - Jul 15th, 2026 7:43 am
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry - Jul 15th, 2026 5:50 am
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026 - Jul 14th, 2026 7:01 am
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients - Jun 25th, 2026 7:15 am
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study - Jun 17th, 2026 6:47 am
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer - Jun 9th, 2026 6:41 am
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development - May 27th, 2026 6:11 am
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know - May 20th, 2026 8:45 am
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity - May 20th, 2026 6:31 am
Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners - May 18th, 2026 8:35 am
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 - May 11th, 2026 7:15 am